Influence of Mycophenolate Mofetil on Preservation of Kidney Function in Liver Transplant Patients

Transplantation Proceedings

Volumn 42, Issue 2, 2010, Pages 651-655

  Barrera Pulido, L ^a   Espinosa Aguilar, M D ^a   Marin D ^a   Nunez Garcia F ^a   Jimenez Perez M ^a   de la Mata Garcia, M ^a   Gomez Bravo M A ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; BILIARY CIRRHOSIS; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEPATITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY PRESERVATION; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY;

CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID;

EID: 77949471149     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.02.016     Document Type: Article

References (10)

1. Mayer A.D., Dmitrewski J., Squifflet J.P., et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 64 (1997) 436
2. Pawarode A., Fine D.M., and Thuluvath P.J. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 9 (2003) 741
3. Moreno J.M., Cuervas-Mons V., Rubio E., et al. Chronic renal dysfunction after liver transplantation in adult patients: prevalence, risk factors, and impact on mortality. Transplant Proc 35 (2003) 1907
4. Pageaux G.P., Rostaing L., Calmus Y., et al. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl 12 (2006) 1755
5. Pfitzmann R., Klupp J., Langrehr J.M., et al. Mycophenolate mofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients. Transplantation 76 (2003) 130
6. Biselli M., Vitale G., Gramenzi A., et al. Two year mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant. Clin Transplant 23 (2009) 191
7. Barrera-Pulido L., Marin D., de la Mata M., et al. Use of mycophenolate mofetil in liver transplantation: Andalusian Liver Registry. Transplant Proc 41 (2009) 2177
8. Svetlana K.-G., Nicolas J., Faouzi S., et al. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY Study. Liver Transplantation 15 (2009) 1083
9. Levey A.S., Eckardt K.U., Tsukamoto Y., et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67 (2005) 2089
10. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31